SMLR

Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.

Wall Street analysts forecast SMLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMLR is 68.50 USD with a low forecast of 51.00 USD and a high forecast of 86.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Semler Scientific Inc revenue for the last quarter amounts to 7.49M USD, decreased -44.56 % YoY.

Semler Scientific Inc. EPS for the last quarter amounts to 1.07 USD, increased 48.61 % YoY.

Semler Scientific Inc (SMLR) has 79 emplpoyees as of January 09 2026.

Today SMLR has the market capitalization of 296.07M USD.